Top Abstracts with Expert Perspective: Plasma Cell Dyscrasias (Myeloma, Amyloidosis etc.)
Tracks
-
| Monday, April 20, 2026 |
| 8:00 AM - 9:30 AM |
| Hall 3A, Upper Level |
Speaker
Dr Matthew Jenner
Consultant Haematologist;
University Hospital Southampton
Session Chair
Dr Rakesh Popat
Consultant Haematologist;
University College London Hospitals
Updated Results of JNJ-5322, a Next-Generation BCMA×GPRC5D×CD3 Trispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
8:00 AM - 8:15 AM
Dr. Mark Grey
Consultant
Blackpool Teaching Hospitals
Teclistamab plus Daratumumab versus Standard of Care in Relapsed/Refractory Multiple Myeloma: Results of MajesTEC-3
8:15 AM - 8:30 AM
Dr Kevin Boyd
Consultant Haematologist
The Royal Marsden
Deep and durable outcomes in patients treated with belantamab mafodotin+pomalidomide+dexamethasone from long-term follow-up of DREAMM-8
8:30 AM - 8:45 AM
Dr Victoria Campbell
Consultant Haematologist
Western General Hospital
Randomized Phase II Dose Optimization Study of Inobrodib (CCS1477) in Combination with Pomalidomide/Dexamethasone in RRMM
8:45 AM - 9:00 AM
Dr James Griffin
Consultant Haematologist
University Hospitals Bristol & Weston
Efficacy of Ciltacabtagene Autoleucel Versus Novel NHS-relevant Regimens in Lenalidomide-Refractory Multiple Myeloma: Matching-Adjusted Indirect Comparison
9:00 AM - 9:15 AM
Dr Mamta Garg
Consultant Haematologist
University Hospital Leicester
Multiple Myeloma Treatment and Survival Trends in the UK: Results from the HONEUR Landmark Cohort
9:15 AM - 9:30 AM
